Human-Albumin, Salzarm Behring (Human Serum Albumin)

Human-Albumin, Salzarm Behring is indicated for clinical situations where rapid expansion of plasma volume or correction of low albumin levels is required.

• Treatment of hypovolemia associated with trauma, surgery, or dehydration.
• Management of hypoalbuminemia in patients with liver disease, nephrotic syndrome, or malnutrition.
• Supportive care for severe burns to maintain circulating volume.
• Adjunct therapy in septic or hemorrhagic shock to improve hemodynamics.
• Use during cardiopulmonary bypass or extracorporeal circulation to prevent fluid shifts.

• Human-Albumin, Salzarm Behring provides exogenous albumin that increases plasma oncotic pressure, thereby drawing water from the interstitial space into the vascular compartment. The added albumin binds endogenous substances such as fatty acids and hormones, stabilizes capillary permeability, and expands intravascular volume, which helps to maintain tissue perfusion and supports hemodynamic stability in patients with low plasma protein or fluid loss.

Adverse reactions to Human-Albumin, Salzarm Behring are generally related to the infusion process or to immune‑mediated responses.

Common

• Mild fever or chills during or shortly after infusion.
• Transient hypotension or hypertension.
• Localized erythema or pruritus at the infusion site.
• Headache or dizziness occurring during administration.

Serious

• Anaphylactic or severe allergic reactions, including bronchospasm and angioedema.
• Acute hemolysis or renal impairment linked to rapid volume shifts.
• Transmission‑related infections, although rare, due to plasma-derived product.

When prescribing Human-Albumin, Salzarm Behring, clinicians should consider several safety aspects to minimize risk.

• Verify patient history for known albumin or plasma product hypersensitivity.
• Assess fluid status and cardiac function before infusion to avoid overload.
• Use a controlled infusion rate; rapid administration may provoke hypotension.
• Monitor vital signs and laboratory parameters (e.g., serum albumin, electrolytes) during therapy.
• Avoid use in patients with severe congestive heart failure unless benefits outweigh risks.
• Document lot numbers and traceability in case of adverse event reporting.

Human-Albumin, Salzarm Behring may influence the pharmacokinetics of other intravenously administered agents, and certain co‑medications can increase the likelihood of infusion reactions.

Avoid

• Concurrent administration of other plasma‑derived products without appropriate monitoring.
• Use with high‑dose diuretics that may exacerbate intravascular volume depletion.
• Simultaneous infusion of vesicant chemotherapy agents that could increase local tissue injury.

Use with caution

• Co‑administration of vasopressors, as volume expansion may alter their dosing requirements.
• Concurrent use of anticoagulants; monitor coagulation parameters due to dilutional effects.
• Administration alongside immunosuppressants, which may mask early signs of allergic reactions.